|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 83.32 EUR | -0.38% |
|
-1.98% | -11.12% |
| 12-12 | Sanofi's Qfitlia and Cablivi Approves in China, Expanding Care for Rare Diseases | CI |
| 12-12 | European health regulator recommends approval for GSK's twice-yearly asthma drug | RE |
MarketScreener Strategies
Search
 | Trump wants to reduce drug prices by up to 80% | May 12, 2025 at 09:45 am |
 | On the stockmarket, the pharmaceutical industry is wary of FDA's new strongman | May 07, 2025 at 11:30 am |
 | Sanofi and Novartis are calling for American drug prices in Europe | April 23, 2025 at 08:26 am |
 | Sanofi : The Doliprane case | October 18, 2024 at 02:16 pm |
 | Sanofi : reportedly receives two bids of 15 billion for its consumer healthcare unit | September 25, 2024 at 10:36 am |
 | Sanofi : In the hot seat | October 30, 2023 at 10:52 am |
 | Sanofi : The road to reinvention | January 10, 2022 at 11:19 am |
 | Sanofi : At a crossroads | August 07, 2018 at 04:56 pm |
No results for this search
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition